EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools

References

• Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton, J., Clements, D., Coraor, N., Grüning, B. A., Guerler, A., Hillman-Jackson, J., Hiltemann, S., Jalili, V., Rasche, H., Soranzo, N., Goecks, J., Taylor, J., Nekrutenko, A., & Blankenberg, D. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Research, 46(W1), W537–W544. https://doi.org/10.1093/nar/gky379
   PubMed Web of Science ®Google Scholar
• Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi, K., Glisson, B., Cetnar, J., Garon, E. B., Schiller, J., Waqar, S. N., Sequist, L. V., Brahmer, J., … Kwiatkowski, D. J., LCMC2 Investigators. (2018). The impact of smoking and TP53 Mutations in lung adenocarcinoma patients with targetable mutations-the Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 24(5), 1038–1047. https://doi.org/10.1158/1078-0432.CCR-17-2289
   PubMed Web of Science ®Google Scholar
• Aliperti, L. A., Predina, J. D., Vachani, A., & Singhal, S. (2011). Local and systemic recurrence is the Achilles heel of cancer surgery. Annals of Surgical Oncology, 18(3), 603–607. https://doi.org/10.1245/s10434-010-1442-0
   PubMed Web of Science ®Google Scholar
• Allison, M. (2010). Turning the tide in lung cancer. Nature Biotechnology, 28(10), 999–1002. https://doi.org/10.1038/nbt1010-999
   PubMed Web of Science ®Google Scholar
• American Cancer Society. (2022). Cancer Facts and Figures 2022.
   Google Scholar
• Andrews, S. (2010). FastQC A quality control tool for high throughput sequence data.
   Google Scholar
• Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A., & Wishart, D. S. (2016). Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Research, 44(W1), W147–W153. https://doi.org/10.1093/nar/gkw419
   PubMed Web of Science ®Google Scholar
• Bai, X.-Y., Zhang, X.-C., Yang, S.-Q., An, S.-J., Chen, Z.-H., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. (2016). Blockade of hedgehog signaling synergistically increases sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer cell lines. PLoS One, 11(3), e0149370. https://doi.org/10.1371/journal.pone.0149370
   PubMed Web of Science ®Google Scholar
• Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., Yefanov, A., Lee, H., Zhang, N., Robertson, CL., Serova, N., Davis, S., & Soboleva, A. (2013). NCBI GEO: Archive for functional genomics data sets–update. Nucleic acids research, 41(Database issue), D991–5. https://doi.org/10.1093/nar/gks1193.
   Google Scholar
• Bhang, H-e. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., Balak, M., Raza, A., Ackley, E., Keen, N., Schlabach, M. R., Palmer, M., Leary, R. J., Chiang, D. Y., Sellers, W. R., … Stegmeier, F. (2015). Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine, 21(5), 440–448. https://doi.org/10.1038/nm.3841
   PubMed Web of Science ®Google Scholar
• Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018). Kinase-targeted cancer therapies: Progress, challenges and future directions. Molecular Cancer, 17(1), 48. https://doi.org/10.1186/s12943-018-0804-2
   PubMedGoogle Scholar
• Blackledge, G., Averbuch, S., Kay, A., & Barton, J. (2000). Anti-EGF receptor therapy. Prostate Cancer and Prostatic Diseases, 3(4), 296–302. https://doi.org/10.1038/sj.pcan.4500488
   PubMed Web of Science ®Google Scholar
• Blakely, C. M., & Bivona, T. G. (2012). Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discovery, 2(10), 872–875. https://doi.org/10.1158/2159-8290.CD-12-0387
   PubMed Web of Science ®Google Scholar
• Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., Newton, W., Bobb, K. L., Fouts, T. R., Meshulam, J., Gubens, M. A., Jablons, D. M., Johnson, J. R., Bandyopadhyay, S., Krogan, N. J., & Bivona, T. G. (2015). NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Reports, 11(1), 98–110. https://doi.org/10.1016/j.celrep.2015.03.012
   PubMed Web of Science ®Google Scholar
• Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England), 30(15), 2114–2120. https://doi.org/10.1093/bioinformatics/btu170
   PubMed Web of Science ®Google Scholar
• Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2014). Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor. Molecular Cancer Therapeutics, 13(1), 60–70. https://doi.org/10.1158/1535-7163.MCT-13-0518
   PubMed Web of Science ®Google Scholar
• Caiazza, F., McCarthy, N. S., Young, L., Hill, A. D. K., Harvey, B. J., & Thomas, W. (2011). Cytosolic phospholipase A2-alpha expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. British Journal of Cancer, 104(2), 338–344. https://doi.org/10.1038/sj.bjc.6606025
   PubMed Web of Science ®Google Scholar
• Casás-Selves, M., Kim, J., Zhang, Z., Helfrich, B. A., Gao, D., Porter, C. C., Scarborough, H. A., Bunn, P. A., Chan, D. C., Tan, A. C., & DeGregori, J. (2012). Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Research, 72(16), 4154–4164. https://doi.org/10.1158/0008-5472.CAN-11-2848
   PubMed Web of Science ®Google Scholar
• Cheng, S.-C., Quintin, J., Cramer, R. A., Shepardson, K. M., Saeed, S., Kumar, V., Giamarellos-Bourboulis, E. J., Martens, J. H. A., Rao, N. A., Aghajanirefah, A., Manjeri, G. R., Li, Y., Ifrim, D. C., Arts, R. J. W., van der Veer, B. M. J. W., Deen, P. M. T., Logie, C., O'Neill, L. A., Willems, P., … Netea, M. G. (2014). mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.), 345(6204), 1250684.
   PubMed Web of Science ®Google Scholar
• Chesnokova, L. S., & Yurochko, A. D. (2021). Using a phosphoproteomic screen to profile early changes during HCMV infection of human monocytes. Methods in Molecular Biology (Clifton, N.J.), 2244, 233–246.
   PubMedGoogle Scholar
• Chiang, C.-T., Demetriou, A. N., Ung, N., Choudhury, N., Ghaffarian, K., Ruderman, D. L., & Mumenthaler, S. M. (2018). mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Cancer Letters, 434, 152–159. https://doi.org/10.1016/j.canlet.2018.07.025
   PubMed Web of Science ®Google Scholar
• Cipriano, R., Bryson, B. L., Miskimen, K. L. S., Bartel, C. A., Hernandez-Sanchez, W., Bruntz, R. C., Scott, S. A., Lindsley, C. W., Brown, H. A., & Jackson, M. W. (2014). Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. Oncogene, 33(25), 3298–3306. https://doi.org/10.1038/onc.2013.293
   PubMed Web of Science ®Google Scholar
• Coelho Ribeiro, M. d. L., Espinosa, J., Islam, S., Martinez, O., Thanki, J. J., Mazariegos, S., Nguyen, T., Larina, M., Xue, B., & Uversky, V. N. (2013). Malleable ribonucleoprotein machine: Protein intrinsic disorder in the Saccharomyces cerevisiae spliceosome. PeerJ, 1, e2. https://doi.org/10.7717/peerj.2
   PubMed Web of Science ®Google Scholar
• de Fijter, J. W. (2017). Cancer and mTOR Inhibitors in Transplant Recipients. Transplantation, 101(1), 45–55. https://doi.org/10.1097/TP.0000000000001447
   PubMed Web of Science ®Google Scholar
• De Rosa, V., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Del Vecchio, S. (2015). Reversal of warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clinical Cancer Research, 21(22), 5110–5120. https://doi.org/10.1158/1078-0432.CCR-15-0375
   PubMed Web of Science ®Google Scholar
• Ding, C.-B., Yu, W.-N., Feng, J.-H., & Luo, J.-M. (2015). Structure and function of Gab2 and its role in cancer (Review). Molecular Medicine Reports, 12(3), 4007–4014. https://doi.org/10.3892/mmr.2015.3951
   PubMed Web of Science ®Google Scholar
• Dong, Z., Meller, J., Succop, P., Wang, J., Wikenheiser-Brokamp, K., Starnes, S., & Lu, S. (2014). Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells. International Journal of Oncology, 45(3), 978–984. https://doi.org/10.3892/ijo.2014.2486
   PubMed Web of Science ®Google Scholar
• Doroshow, D. B., & Herbst, R. S. (2018). Treatment of advanced non-small cell lung cancer in 2018. JAMA Oncology, 4(4), 569–570. https://doi.org/10.1001/jamaoncol.2017.5190
   PubMed Web of Science ®Google Scholar
• Dosztányi, Z., Csizmok, V., Tompa, P., & Simon, I. (2005). IUPred: Web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics (Oxford, England), 21(16), 3433–3434.
   PubMed Web of Science ®Google Scholar
• Dosztanyi, Z., et al. (2005). The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. Journal of Molecular Biology, 347(4), 827–839.
   PubMed Web of Science ®Google Scholar
• Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., & Milenkova, T. (2014). First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. British Journal of Cancer, 110(1), 55–62. https://doi.org/10.1038/bjc.2013.721
   PubMed Web of Science ®Google Scholar
• Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021). Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (Cambridge (MA)), 2(2), 100103. https://doi.org/10.1016/j.xinn.2021.100103
   PubMedGoogle Scholar
• Economopoulou, P., & Mountzios, G. (2018). The emerging treatment landscape of advanced non-small cell lung cancer. Annals of Translational Medicine, 6(8), 138. https://doi.org/10.21037/atm.2017.11.07
   PubMed Web of Science ®Google Scholar
• Fedor, D., Johnson, W. R., & Singhal, S. (2013). Local recurrence following lung cancer surgery: Incidence, risk factors, and outcomes. Surgical Oncology, 22(3), 156–161. https://doi.org/10.1016/j.suronc.2013.04.002
   PubMed Web of Science ®Google Scholar
• Goetzman, E. S., & Prochownik, E. V. (2018). The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front Endocrinol (Lausanne), 9, 129.
   PubMed Web of Science ®Google Scholar
• Gringeri, E., Carraro, A., Tibaldi, E., D'Amico, F. E., Mancon, M., Toninello, A., Pagano, M. A., Vio, C., Cillo, U., & Brunati, A. M. (2009). Lyn-mediated mitochondrial tyrosine phosphorylation is required to preserve mitochondrial integrity in early liver regeneration. The Biochemical Journal, 425(2), 401–412. https://doi.org/10.1042/BJ20090902
   PubMedGoogle Scholar
• Han, W., & Lo, H. W. (2012). Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters, 318(2), 124–134. https://doi.org/10.1016/j.canlet.2012.01.011
   PubMed Web of Science ®Google Scholar
• Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H-e. C., Krishnamurthy Radhakrishna, V., Siravegna, G., Hu, H., Raoof, S., Lockerman, E., Kalsy, A., Lee, D., Keating, C. L., Ruddy, D. A., Damon, L. J., … Engelman, J. A. (2016). Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 22(3), 262–269. https://doi.org/10.1038/nm.4040
   PubMed Web of Science ®Google Scholar
• He, B., Wang, K., Liu, Y., Xue, B., Uversky, V. N., & Dunker, A. K. (2009). Predicting intrinsic disorder in proteins: An overview. Cell Research, 19(8), 929–949. https://doi.org/10.1038/cr.2009.87
   PubMed Web of Science ®Google Scholar
• He, J., Huang, Z., Han, L., Gong, Y., & Xie, C. (2021). Mechanisms and management of 3rdgeneration EGFRTKI resistance in advanced nonsmall cell lung cancer. International Journal of Oncology, 59(5). https://doi.org/10.3892/ijo.2021.5270
   Web of Science ®Google Scholar
• Hirsh, V. (2011). Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncology (London, England), 7(7), 817–825. https://doi.org/10.2217/fon.11.62
   PubMed Web of Science ®Google Scholar
• Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: An overview. Cancers (Basel), 6(3), 1769–1792. https://doi.org/10.3390/cancers6031769
   PubMed Web of Science ®Google Scholar
• Howell, M. C., G, R., Khalil, R., Foran, E., Quarni, W., Nair, R., Stevens, S., Grinchuk, A., Hanna, A., Mohapatra, S., & Mohapatra, S. (2020). Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis. FASEB BioAdvances, 2(2), 90–105. https://doi.org/10.1096/fba.2019-00081
   PubMedGoogle Scholar
• Huang, F. (2012). Subclassifying disordered proteins by the CH-CDF plot method. Pacific Symposium on Biocomputing, 128–139.
   Google Scholar
• Huang, F., Oldfield, C. J., Xue, B., Hsu, W.-L., Meng, J., Liu, X., Shen, L., Romero, P., Uversky, V. N., & Dunker, A. K. (2014). Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics, 15(S17), S4. https://doi.org/10.1186/1471-2105-15-S17-S4
   PubMedGoogle Scholar
• Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradović, Z., & Dunker, A. K. (2002). Intrinsic disorder in cell-signaling and cancer-associated proteins. Journal of Molecular Biology, 323(3), 573–584. https://doi.org/10.1016/S0022-2836(02)00969-5
   PubMed Web of Science ®Google Scholar
• Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Research, 68(21), 8673–8677. https://doi.org/10.1158/0008-5472.CAN-08-2097
   PubMed Web of Science ®Google Scholar
• Katayama, Y., Yamada, T., Tokuda, S., Okura, N., Nishioka, N., Morimoto, K., Tanimura, K., Morimoto, Y., Iwasaku, M., Horinaka, M., Sakai, T., Kita, K., Yano, S., & Takayama, K. (2022). Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells. Cancer Medicine, 11(4), 944–955. https://doi.org/10.1002/cam4.4504
   PubMed Web of Science ®Google Scholar
• Kesarwani, M., Kincaid, Z., Gomaa, A., Huber, E., Rohrabaugh, S., Siddiqui, Z., Bouso, M. F., Latif, T., Xu, M., Komurov, K., Mulloy, J. C., Cancelas, J. A., Grimes, H. L., & Azam, M. (2017). Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nature Medicine, 23(4), 472–482. https://doi.org/10.1038/nm.4310
   PubMed Web of Science ®Google Scholar
• Kim, D., Langmead, B., & Salzberg, S. L. (2015). HISAT: A fast spliced aligner with low memory requirements. Nature Methods, 12(4), 357–360. https://doi.org/10.1038/nmeth.3317
   PubMed Web of Science ®Google Scholar
• Kim, P. M., Sboner, A., Xia, Y., & Gerstein, M. (2008). The role of disorder in interaction networks: A structural analysis. Molecular Systems Biology, 4(179), 179.
   PubMedGoogle Scholar
• Kim, S., Im, J. H., Kim, W. K., Choi, Y. J., Lee, J.-Y., Kim, S. K., Kim, S. J., Kwon, S. W., & Kang, K. W. (2021). Enhanced sensitivity of nonsmall cell lung cancer with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors to phenformin: The roles of a metabolic shift to oxidative phosphorylation and redox balance. Oxidative Medicine and Cellular Longevity, 2021, 5428364.
   PubMed Web of Science ®Google Scholar
• Kramer, A., et al. (2014). Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics, 30(4), 523–530.
   PubMed Web of Science ®Google Scholar
• Krause, D. S., & Van Etten, R. A. (2005). Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine, 353(2), 172–187. https://doi.org/10.1056/NEJMra044389
   PubMed Web of Science ®Google Scholar
• Kwapiszewski, R., Pawlak, S. D., & Adamkiewicz, K. (2016). Anti-EGFR agents: Current status, forecasts and future directions. Targeted Oncology, 11(6), 739–752. https://doi.org/10.1007/s11523-016-0456-3
   PubMed Web of Science ®Google Scholar
• Lee, C. S., Kim, K. L., Jang, J. H., Choi, Y. S., Suh, P.-G., & Ryu, S. H. (2009). The roles of phospholipase D in EGFR signaling. Biochimica et Biophysica Acta, 1791(9), 862–868. https://doi.org/10.1016/j.bbalip.2009.04.007
   PubMed Web of Science ®Google Scholar
• Liao, Y., Smyth, G. K., & Shi, W. (2014). featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics (Oxford, England), 30(7), 923–930. https://doi.org/10.1093/bioinformatics/btt656
   PubMed Web of Science ®Google Scholar
• Lim, S. M., Syn, N. L., Cho, B. C., & Soo, R. A. (2018). Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews, 65, 1–10. https://doi.org/10.1016/j.ctrv.2018.02.006
   PubMed Web of Science ®Google Scholar
• Lin, Y.-C., Lin, Y.-C., Shih, J.-Y., Huang, W.-J., Chao, S.-W., Chang, Y.-L., & Chen, C.-C. (2015). DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers. Clinical Cancer Research, 21(2), 428–438. https://doi.org/10.1158/1078-0432.CCR-14-1150
   PubMed Web of Science ®Google Scholar
• Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550. https://doi.org/10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Martin, M. J., Eberlein, C., Taylor, M., Ashton, S., Robinson, D., & Cross, D. (2016). Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. Oncotarget, 7(52), 86313–86325. https://doi.org/10.18632/oncotarget.13388
   PubMedGoogle Scholar
• Mohan, A., Sullivan, W. J., Radivojac, P., Dunker, A. K., & Uversky, V. N. (2008). Intrinsic disorder in pathogenic and non-pathogenic microbes: Discovering and analyzing the unfoldomes of early-branching eukaryotes. Molecular bioSystems, 4(4), 328–340. https://doi.org/10.1039/b719168e
   PubMedGoogle Scholar
• Obradovic, Z., Peng, K., Vucetic, S., Radivojac, P., & Dunker, A. K. (2005). Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins: Structure, Function, and Bioinformatics, 61(S7), 176–182. https://doi.org/10.1002/prot.20735
   PubMed Web of Science ®Google Scholar
• Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013). Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology, 31(8), 1070–1080. https://doi.org/10.1200/JCO.2012.43.3912
   PubMed Web of Science ®Google Scholar
• Okimoto, R. A., Breitenbuecher, F., Olivas, V. R., Wu, W., Gini, B., Hofree, M., Asthana, S., Hrustanovic, G., Flanagan, J., Tulpule, A., Blakely, C. M., Haringsma, H. J., Simmons, A. D., Gowen, K., Suh, J., Miller, V. A., Ali, S., Schuler, M., & Bivona, T. G. (2017). Inactivation of Capicua drives cancer metastasis. Nature Genetics, 49(1), 87–96. https://doi.org/10.1038/ng.3728
   PubMed Web of Science ®Google Scholar
• Okon, I. S., Coughlan, K. A., Zhang, M., Wang, Q., & Zou, M.-H. (2015). Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. The Journal of Biological Chemistry, 290(14), 9101–9110. https://doi.org/10.1074/jbc.M114.631580
   PubMed Web of Science ®Google Scholar
• Oldfield, C. J., Cheng, Y., Cortese, M. S., Brown, C. J., Uversky, V. N., & Dunker, A. K. (2005). Comparing and combining predictors of mostly disordered proteins. Biochemistry, 44(6), 1989–2000. https://doi.org/10.1021/bi047993o
   PubMed Web of Science ®Google Scholar
• Oronsky, B., Ma, P., Reid, T. R., Cabrales, P., Lybeck, M., Oronsky, A., Oronsky, N., & Carter, C. A. (2018). Navigating the "no man’s land" of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): A review. Neoplasia (New York, N.Y.), 20(1), 92–98. https://doi.org/10.1016/j.neo.2017.11.001
   PubMed Web of Science ®Google Scholar
• Papa, S., Choy, P. M., & Bubici, C. (2019). The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene, 38(13), 2223–2240. https://doi.org/10.1038/s41388-018-0582-8
   PubMed Web of Science ®Google Scholar
• Parikh, P., & Puri, T. (2013). Personalized medicine: Lung Cancer leads the way. Indian Journal of Cancer, 50(2), 77–79. https://doi.org/10.4103/0019-509X.117005
   PubMed Web of Science ®Google Scholar
• Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021). Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer, 2(4), 377–391. https://doi.org/10.1038/s43018-021-00195-8
   PubMedGoogle Scholar
• Peacock, J. W., Takeuchi, A., Hayashi, N., Liu, L., Tam, K. J., Al Nakouzi, N., Khazamipour, N., Tombe, T., Dejima, T., Lee, K. C., Shiota, M., Thaper, D., Lee, W. C., Hui, D. H., Kuruma, H., Ivanova, L., Yenki, P., Jiao, I. Z., Khosravi, S., … Ong, C. J. (2018). SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Molecular Medicine, 10(2), 219–238. https://doi.org/10.15252/emmm.201707689
   PubMed Web of Science ®Google Scholar
• Peng, K., Radivojac, P., Vucetic, S., Dunker, A. K., & Obradovic, Z. (2006). Length-dependent prediction of protein intrinsic disorder. BMC Bioinformatics, 7(1), 208. https://doi.org/10.1186/1471-2105-7-208
   PubMed Web of Science ®Google Scholar
• Peng, K., Vucetic, S., Radivojac, P., Brown, C. J., Dunker, A. K., & Obradovic, Z. (2005). Optimizing long intrinsic disorder predictors with protein evolutionary information. Journal of Bioinformatics and Computational Biology, 3(1), 35–60. https://doi.org/10.1142/s0219720005000886
   PubMedGoogle Scholar
• Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., Vaidya, M. P., Arnold, L. D., Doty, J. L., Iwata, K. K., & Morin, M. J. (1999). Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. The Journal of Pharmacology and Experimental Therapeutics, 291(2), 739–748.
   PubMed Web of Science ®Google Scholar
• Romero, P., Obradovic, Z., Li, X., Garner, E. C., Brown, C. J., & Dunker, A. K. (2001). Sequence complexity of disordered protein. Proteins: Structure, Function, and Genetics, 42(1), 38–48. https://doi.org/10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Rosell, R., Cardona, A. F., Arrieta, O., Aguilar, A., Ito, M., Pedraz, C., Codony-Servat, J., & Santarpia, M. (2021). Coregulation of pathways in lung cancer patients with EGFR mutation: Therapeutic opportunities. British Journal of Cancer, 125(12), 1602–1611. https://doi.org/10.1038/s41416-021-01519-2
   PubMed Web of Science ®Google Scholar
• Scarborough, H. A., Helfrich, B. A., Casás-Selves, M., Schuller, A. G., Grosskurth, S. E., Kim, J., Tan, A.-C., Chan, D. C., Zhang, Z., Zaberezhnyy, V., Bunn, P. A., & DeGregori, J. (2017). AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clinical Cancer Research, 23(6), 1531–1541. https://doi.org/10.1158/1078-0432.CCR-16-1179
   PubMed Web of Science ®Google Scholar
• Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012). Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research, 18(18), 4986–4996. https://doi.org/10.1158/1078-0432.CCR-12-0792
   PubMed Web of Science ®Google Scholar
• Song, J.-Y., Kim, C.-S., Lee, J.-H., Jang, S. J., Lee, S-w., Hwang, J. J., Lim, C., Lee, G., Seo, J., Cho, S. Y., & Choi, J. (2013). Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Investigational New Drugs, 31(6), 1458–1465. https://doi.org/10.1007/s10637-013-0030-0
   PubMed Web of Science ®Google Scholar
• Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., Coon, C. M., Windle, B. E., Oya, Y., Koblinski, J. E., Harada, H., Leverson, J. D., Souers, A. J., Hata, A. N., Boikos, S., … Faber, A. C. (2018). Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target. Clinical Cancer Research, 24(22), 5658–5672. https://doi.org/10.1158/1078-0432.CCR-18-0304
   PubMed Web of Science ®Google Scholar
• Sun, Y., Daemen, A., Hatzivassiliou, G., Arnott, D., Wilson, C., Zhuang, G., Gao, M., Liu, P., Boudreau, A., Johnson, L., & Settleman, J. (2014). Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer & Metabolism, 2(1), 20. https://doi.org/10.1186/2049-3002-2-20
   PubMedGoogle Scholar
• Tang, Z., Du, R., Jiang, S., Wu, C., Barkauskas, D. S., Richey, J., Molter, J., Lam, M., Flask, C., Gerson, S., Dowlati, A., Liu, L., Lee, Z., Halmos, B., Wang, Y., Kern, J. A., & Ma, P. C. (2008). Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. British Journal of Cancer, 99(6), 911–922. https://doi.org/10.1038/sj.bjc.6604559
   PubMed Web of Science ®Google Scholar
• Tong, C. W. S., Wu, W. K. K., Loong, H. H. F., Cho, W. C. S., & To, K. K. W. (2017). Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Letters, 405, 100–110. https://doi.org/10.1016/j.canlet.2017.07.023
   PubMed Web of Science ®Google Scholar
• Treue, D., Bockmayr, M., Stenzinger, A., Heim, D., Hester, S., & Klauschen, F. (2019). Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer. International Journal of Cancer, 144(3), 545–557. https://doi.org/10.1002/ijc.31845
   PubMed Web of Science ®Google Scholar
• Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016). Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open, 1(5), e000088. https://doi.org/10.1136/esmoopen-2016-000088
   PubMed Web of Science ®Google Scholar
• Uversky, V. N., Gillespie, J. R., & Fink, A. L. (2000). Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins: Structure, Function, and Genetics, 41(3), 415–427. https://doi.org/10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Van Bibber, N. W., et al. (2020). Intrinsic disorder in tetratricopeptide repeat proteins. International Journal of Molecular Sciences. (10), 21.
   PubMed Web of Science ®Google Scholar
• Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., & Heasley, L. E. (2013). A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis, 2(3), e39. https://doi.org/10.1038/oncsis.2013.4
   PubMed Web of Science ®Google Scholar
• Wright, P. E., & Dyson, H. J. (1999). Intrinsically unstructured proteins: Re-assessing the protein structure-function paradigm. Journal of Molecular Biology, 293(2), 321–331. https://doi.org/10.1006/jmbi.1999.3110
   PubMed Web of Science ®Google Scholar
• Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002). Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene, 21(41), 6255–6263. https://doi.org/10.1038/sj.onc.1205794
   PubMed Web of Science ®Google Scholar
• Xue, B., Dunbrack, R. L., Williams, R. W., Dunker, A. K., & Uversky, V. N. (2010). PONDR-FIT: A meta-predictor of intrinsically disordered amino acids. Biochimica et Biophysica Acta, 1804(4), 996–1010. https://doi.org/10.1016/j.bbapap.2010.01.011
   PubMed Web of Science ®Google Scholar
• Xue, B., Oldfield, C. J., Dunker, A. K., & Uversky, V. N. (2009). CDF it all: Consensus prediction of intrinsically disordered proteins based on various cumulative distribution functions. FEBS Letters, 583(9), 1469–1474. https://doi.org/10.1016/j.febslet.2009.03.070
   PubMed Web of Science ®Google Scholar
• Yamaoka, T., Ohmori, T., Ohba, M., Arata, S., Kishino, Y., Murata, Y., Kusumoto, S., Ishida, H., Shirai, T., Hirose, T., Ohnishi, T., & Sasaki, Y. (2016). Acquired resistance mechanisms to combination Met-TKI/EGFR-TKI exposure in met-amplified EGFR-TKI-resistant lung adenocarcinoma harboring an activating EGFR mutation. Molecular Cancer Therapeutics, 15(12), 3040–3054. https://doi.org/10.1158/1535-7163.MCT-16-0313
   PubMed Web of Science ®Google Scholar
• Ye, M., Wang, S., Wan, T., Jiang, R., Qiu, Y., Pei, L., Pang, N., Huang, Y., Huang, Y., Zhang, Z., & Yang, L. (2017). Combined inhibitions of glycolysis and AKT/autophagy can overcome resistance to EGFR-targeted therapy of lung cancer. Journal of Cancer, 8(18), 3774–3784. https://doi.org/10.7150/jca.21035
   PubMed Web of Science ®Google Scholar
• Zhang, X.-Y., Zhang, Y.-K., Wang, Y.-J., Gupta, P., Zeng, L., Xu, M., Wang, X.-Q., Yang, D.-H., & Chen, Z.-S. (2016). Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Molecules, 21(9), 1236. https://doi.org/10.3390/molecules21091236
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Kobayashi, S., Borczuk, A. C., Leidner, R. S., Laframboise, T., Levine, A. D., & Halmos, B. (2010). Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis, 31(4), 577–586. https://doi.org/10.1093/carcin/bgq020
   PubMed Web of Science ®Google Scholar
• Zhao, C., Du, G., Skowronek, K., Frohman, M. A., & Bar-Sagi, D. (2007). Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nature Cell Biology, 9(6), 706–712. https://doi.org/10.1038/ncb1594
   PubMed Web of Science ®Google Scholar
• Zhong, W. Z., Zhou, Q., & Wu, Y. L. (2017). The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. Oncotarget, 8(41), 71358–71370. https://doi.org/10.18632/oncotarget.20311
   PubMedGoogle Scholar